Product Images Alendronate Sodium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 11 images provide visual information about the product associated with Alendronate Sodium NDC 64980-342 by Rising Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 - alendronate fig1
The text describes the cumulative incidence of hip fractures in a three-year study involving patients with radiographic vertebral fracture at baseline. The incidence is represented as a percentage and plotted over time in months, with separate lines for the placebo and alendronate sodium treatments.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 70 mg Blister Carton (4 Unit-of-use) - alendronate fig10
The text is a label of a medication named "Rising® NDC 64080-342-14" which is "Once Weekly Alendronate Sodium Tablets, USP". The pharmacist is instructed to dispense the medication guide to the patient and there are four tablets in the packaging. It also includes space for a prescription label to be applied.*
Figure 2 - alendronate fig2
This text represents the results of the osteoporosis treatment studies in postmenopausal women, specifically the increase in BMD (Bone Mineral Density) after taking Alendronate 10 mg/day for three years. The results show a mean increase of 12% in BMD, relative to Placebo, at the lumbar spine. The femoral neck and trochanter also saw increases in BMD, but the specific percentages are not available due to the text being cut off.*
Figure 3 - alendronate fig3
This is a chart presenting results from a study that evaluated the effect of Alendronate 10 mg/day versus a placebo on postmenopausal women with osteoporosis. The chart shows the mean percentage change from baseline in the lumbar spine bone mineral density (BMD) over a period of 36 months. The study was multinational and the results show that the group receiving Alendronate 10 mg/day had a higher BMD compared to the placebo group.*
Figure 4 - alendronate fig4
Figure 5 - alendronate fig5
Figure 6 - alendronate fig6
The text is providing data on the effect of Alendronate 40 mg/day on serum alkaline phosphatase in comparison to Placebo or Etidronate 400 mg/day in studies of Paget’s Disease of Bone. The data is presented in a chart showing the mean % change from baseline over a period of 6 months with 0, 3, and 6 months marked on the horizontal axis. There are separate results for a multinational study and a U.S. study, with sample sizes of 27 and 41 respectively.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg (30 Tablets Bottle) - alendronate fig7
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg (100 Tablets Bottle) - alendronate fig8
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 35 mg Blister Carton (4 Unit-of-use) - alendronate fig9
Rising® NDG 64080.341 14 is a medication containing Alendronate Sodium in tablet form, which is taken once every week. The pharmacist is advised to provide the patient with a medication guide. The rest of the text is not-readable and contains errors.*
Chemical Structure - alendronate str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.